pyridines

Summary

Summary: Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.

Top Publications

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  2. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  4. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
  5. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
  6. ncbi Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
    Daniel D Von Hoff
    Translational Genomics Research Institute and Scottsdale Healthcare, Scottsdale, AZ, USA
    N Engl J Med 361:1164-72. 2009
  7. ncbi A ROCK inhibitor permits survival of dissociated human embryonic stem cells
    Kiichi Watanabe
    Organogenesis and Neurogenesis Group, Center for Developmental Biology, RIKEN, Kobe 650 0047, Japan
    Nat Biotechnol 25:681-6. 2007
  8. ncbi p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain
    Shan-Xue Jin
    Neural Plasticity Research Group, Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
    J Neurosci 23:4017-22. 2003
  9. ncbi Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1)
    Linda Vermeulen
    Department of Molecular Biology, University of Gent VIB, K L Ledeganckstraat 35, B 9000 Gent, Belgium
    EMBO J 22:1313-24. 2003
  10. ncbi Phase II trial of sorafenib in advanced thyroid cancer
    Vandana Gupta-Abramson
    Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 26:4714-9. 2008

Detail Information

Publications316 found, 100 shown here

  1. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  2. ncbi Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  4. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
    ....
  5. ncbi Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    Joanne van Ryn
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Thromb Haemost 103:1116-27. 2010
    ....
  6. ncbi Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
    Daniel D Von Hoff
    Translational Genomics Research Institute and Scottsdale Healthcare, Scottsdale, AZ, USA
    N Engl J Med 361:1164-72. 2009
    ..In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug...
  7. ncbi A ROCK inhibitor permits survival of dissociated human embryonic stem cells
    Kiichi Watanabe
    Organogenesis and Neurogenesis Group, Center for Developmental Biology, RIKEN, Kobe 650 0047, Japan
    Nat Biotechnol 25:681-6. 2007
    ..We demonstrate that the protective ability of Y-27632 enables SFEB-cultured hES cells to survive and differentiate into Bf1(+) cortical and basal telencephalic progenitors, as do SFEB-cultured mouse ES cells...
  8. ncbi p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain
    Shan-Xue Jin
    Neural Plasticity Research Group, Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
    J Neurosci 23:4017-22. 2003
    ..Coactivation of p38 in DRG neurons and spinal microglia may contribute to later phases of neuropathic pain...
  9. ncbi Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1)
    Linda Vermeulen
    Department of Molecular Biology, University of Gent VIB, K L Ledeganckstraat 35, B 9000 Gent, Belgium
    EMBO J 22:1313-24. 2003
    ..This effect represents, together with phosphorylation of nucleosome components such as histone H3, an essential step leading to selective transcriptional activation of NF-kappaB-dependent gene expression...
  10. ncbi Phase II trial of sorafenib in advanced thyroid cancer
    Vandana Gupta-Abramson
    Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 26:4714-9. 2008
    ....
  11. ncbi Drugging the PI3 kinome: from chemical tools to drugs in the clinic
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, Section of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom
    Cancer Res 70:2146-57. 2010
    ..The challenges and outlook for drugging the PI3 kinome are discussed in the more general context of the role of structural biology and chemical biology in innovative drug discovery...
  12. ncbi Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  13. ncbi Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am Heart J 157:805-10, 810.e1-2. 2009
    ..The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009...
  14. ncbi Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, York, NY 10022, USA
    J Clin Oncol 24:4293-300. 2006
    ..This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients...
  15. ncbi Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
    ..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
  16. ncbi Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    N Engl J Med 361:1173-8. 2009
    ....
  17. ncbi A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
    J C Lee
    Department of Cellular Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
    Nature 372:739-46. 1994
    ..Binding of the pyridinyl-imidazole compounds inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine production, suggesting that the CSBPs are critical for cytokine production...
  18. ncbi Phase II trial of sorafenib in metastatic thyroid cancer
    Richard T Kloos
    Ohio State University, Department of Internal Medicine, Molecular Virology, Immunology, and Genetics, Pathology, Radiology, Center for Biostatistics, Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:1675-84. 2009
    ..Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC...
  19. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ....
  20. ncbi Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors
    Valerie B Caraiscos
    Institute of Medical Science, Department of Anesthesia, University of Toronto, Toronto, ON, Canada M5S 1A8
    Proc Natl Acad Sci U S A 101:3662-7. 2004
    ....
  21. ncbi Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany
    Oncologist 12:426-37. 2007
    ..Based on these findings, continuous daily 400 mg bid sorafenib was chosen as the optimal regimen for phase II/III studies. Trials are ongoing in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer...
  22. ncbi Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate
    Neil S Roskell
    Neil Roskell, RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK
    Thromb Haemost 104:1106-15. 2010
    ..There was no indication of increased intracranial or extracranial haemorrhage with dabigatran etexilate compared to antiplatelet agents...
  23. ncbi Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 17:2502-11. 2011
    ..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed...
  24. ncbi Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective
    S V Sorensen
    United BioSource Corporation, Bethesda, Maryland, USA
    Thromb Haemost 105:908-19. 2011
    ..This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients...
  25. ncbi Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    ..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma...
  26. ncbi Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents
    W P Spooren
    Novartis Pharma AG, Nervous System Research, Basel, Switzerland
    J Pharmacol Exp Ther 295:1267-75. 2000
    ..5 mg/kg) locomotor activity in mice and prepulse inhibition in rats (1, 3, or 10 mg/kg). Thus, these findings indicate that MPEP exhibits anxiolytic-like effects and low risks for sedation and psychotomimetic side-effects in rodents...
  27. ncbi Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  28. ncbi The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine
    Michael C Montana
    Washington University Pain Center, Department of Anesthesiology, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Pharmacol Exp Ther 330:834-43. 2009
    ..These results demonstrate that fenobam is analgesic in mice and has an improved in vivo selectivity for mGlu5 over MPEP...
  29. ncbi Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors
    Arati Sharma
    Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey 17033, USA
    Cancer Res 65:2412-21. 2005
    ..Thus, these studies identify the mechanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development and show the effectiveness of targeting this protein to inhibit melanoma tumor growth...
  30. ncbi A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo
    A Iwamaru
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 26:2435-44. 2007
    ..We conclude that WP1066 holds promise as a therapeutic agent against malignant gliomas...
  31. ncbi Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
    Madeleine M Hipp
    Department of Hematology, Oncology and Immunology, University of Tubingen, Tubingen, Germany
    Blood 111:5610-20. 2008
    ..These results indicate that sunitinib, but not sorafenib, is suitable for combination with immunotherapeutic approaches for treatment of cancer patients...
  32. ncbi The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Joachim Stangier
    Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, Germany
    Br J Clin Pharmacol 64:292-303. 2007
    ..Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects...
  33. ncbi Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
    Carol Pena
    Bayer HealthCare Pharmaceuticals, Montville, New Jersey 07045 1000, USA
    Clin Cancer Res 16:4853-63. 2010
    ....
  34. ncbi Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, AP HP, Paris University of Paris Diderot, Paris 7, France
    Lancet 372:646-55. 2008
    ..We compared these two combinations directly in treatment-naive patients...
  35. ncbi Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence
    Yue Hao
    Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, California, USA
    Biol Psychiatry 68:240-8. 2010
    ..We examined here whether neuroadaptive dysregulation of metabotropic glutamate receptor function is a factor in escalating cocaine self-administration...
  36. ncbi Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro
    Anders Ullen
    Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 17176 Stockholm, Sweden
    Int J Oncol 37:15-20. 2010
    ....
  37. ncbi Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
    James G Christensen
    Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, La Jolla, CA 92121, USA
    Mol Cancer Ther 6:3314-22. 2007
    ..Collectively, these data illustrate the potential clinical utility of inhibitors of NPM-ALK in treatment of patients with ALK-positive ALCL...
  38. ncbi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
    ..In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed...
  39. ncbi Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    James E Butrynski
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:1727-33. 2010
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  40. ncbi The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
    Takaaki Sasaki
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, D820, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 70:10038-43. 2010
    ..Our findings highlight the importance of studying drug resistance mechanisms in order to develop effective clinical treatments for patients with ALK-translocated cancers...
  41. ncbi Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 108:7535-40. 2011
    ..Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations...
  42. ncbi Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
    ..Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
  43. ncbi Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP
    Jill L Silverman
    Laboratory of Behavioral Neuroscience, National Institute of Mental Health, Porter Neuroscience Research Center, Bethesda, MD 20892, USA
    Neuropsychopharmacology 35:976-89. 2010
    ..Our findings suggest that antagonists of mGluR5 receptors may have selective therapeutic efficacy in treating repetitive behaviors in autism...
  44. ncbi A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077
    C D Britten
    Cancer Therapy and Research Center, Institute for Drug Development, and The University of Texas Health Science Center at San Antonio, 78229, USA
    Clin Cancer Res 6:42-9. 2000
    ....
  45. ncbi Nicotinic acetylcholine receptors: an overview on drug discovery
    Dieter D'Hoedt
    Department of Neurosciences, CMU, Geneve, Switzerland
    Expert Opin Ther Targets 13:395-411. 2009
    ..Results/conclusion: Long-standing efforts in this field should soon result in the finding of new molecules that might be applicable to situations ranging from neurological diseases to immune treatments...
  46. ncbi Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    F Barkhof
    Department of Radiology, VU University Medical Center, MB, Amsterdam, The Netherlands
    Neurology 74:1033-40. 2010
    ..This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS...
  47. ncbi Effect of ROCK inhibitor Y-27632 on normal and variant human embryonic stem cells (hESCs) in vitro: its benefits in hESC expansion
    Kalamegam Gauthaman
    Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore
    Stem Cell Rev 6:86-95. 2010
    ..The results confirmed that Y-27632 is a useful agent that aids in the expansion of undifferentiated hESC numbers for downstream applications in regenerative medicine...
  48. ncbi p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting
    J M McClung
    Exercise Biochemistry Laboratory, University of Florida, Gainesville, Florida, USA
    Am J Physiol Cell Physiol 298:C542-9. 2010
    ....
  49. ncbi Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells
    Lu Chen
    Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 69:8853-61. 2009
    ..Because most ER-negative breast tumors express mutant p53, our results provide the foundation for future development of p38 inhibitors to target p38 for the treatment of p53 mutant and ER-negative breast cancers...
  50. ncbi Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    ..The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC)...
  51. ncbi GDC-0449--targeting the hedgehog signaling pathway
    Christine Dierks
    Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Recent Results Cancer Res 184:235-8. 2010
    ..It was successfully tested in a phase-I clinical trial demonstrating good pharmacodynamic (PD) and pharmacokinetic (PK) properties and showing objective response and clinical benefit in several patients with basal cell carcinoma...
  52. ncbi Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9
    Keisuke Kohga
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
    Hepatology 51:1264-73. 2010
    ..Conclusion: ADAM9 is involved in MICA ectodomain shedding in HCC cells, and sorafenib can modulate ADAM9 expression. Sorafenib therapy may have a previously unrecognized effect on antitumor immunity in patients with HCC...
  53. ncbi Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning
    A Gravius
    Preclinical R and D, Merz Pharmaceuticals, Frankfurt am Main, Germany
    Behav Pharmacol 16:113-21. 2005
    ..5 and 5 mg/kg inhibited fear conditioning in the FPS when tested 24 h later. In contrast, EMQMCM was ineffective. Our findings suggest diverse involvement of mGlu1 and mGlu5 receptors in negatively reinforced learning...
  54. ncbi Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo
    David B Ring
    Chiron Corporation, Emeryville, California, USA
    Diabetes 52:588-95. 2003
    ..Collectively, our results suggest that these selective GSK-3 inhibitors may be useful as acute-acting therapeutics for the treatment of the insulin resistance of type 2 diabetes...
  55. ncbi Chloropyridinyl neonicotinoid insecticides: diverse molecular substituents contribute to facile metabolism in mice
    Kevin A Ford
    Environmental Chemistry and Toxicology Laboratory, Department of Environmental Science, Policy and Management, University of California, Berkeley, 94720-3112, USA
    Chem Res Toxicol 19:944-51. 2006
  56. ncbi Sphingosine 1-phosphate stimulates smooth muscle cell differentiation and proliferation by activating separate serum response factor co-factors
    Kashelle Lockman
    Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 279:42422-30. 2004
    ..Taken together these results demonstrate that S1P activates multiple signaling pathways in SMC and regulates proliferation by ERK-dependent activation of Elk-1 and differentiation by RhoA-dependent activation of MRTF-A...
  57. ncbi Myosin light chain kinase activation and calcium sensitization in smooth muscle in vivo
    Yusuke Mizuno
    Dept Physiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9040, USA
    Am J Physiol Cell Physiol 295:C358-64. 2008
    ..Thus the onset of agonist-induced contraction in phasic smooth muscle results from the rapid and coordinated activation of MLCK with hierarchical inhibition of MLCP by CPI-17 and MYPT1 phosphorylation...
  58. ncbi NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats
    Chang Shi
    Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, PR China
    Toxicol Lett 173:161-7. 2007
    ..The application of (1)H NMR spectroscopy to an array of biological samples comprising urine, serum and liver tissue extracts yields new insight into the hepatotoxicity of xenobiotics...
  59. ncbi Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
    D Handolias
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Br J Cancer 102:1219-23. 2010
    ..Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation...
  60. ncbi Presence of a ROCK inhibitor in extracellular matrix supports more undifferentiated growth of feeder-free human embryonic and induced pluripotent stem cells upon passaging
    Mohammad Pakzad
    Department of Stem Cells and Developmental Biology, Royan Institute for Stem Cell Biology and Technology, ACECR, P O Box 19395 4644, Tehran, Iran
    Stem Cell Rev 6:96-107. 2010
    ..This is due not only to an anti-apoptotic effect, but also to an increase in the ECM-cells interaction. Therefore, we believe this method will be useful for both current and future applications of these pluripotent stem cells...
  61. ncbi NO-independent stimulators of soluble guanylate cyclase
    A Straub
    Institute of Medicinal Chemistry, Pharma Research Centre, Bayer AG, Wuppertal, FRG
    Bioorg Med Chem Lett 11:781-4. 2001
    ..Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application...
  62. ncbi NO-independent regulatory site on soluble guanylate cyclase
    J P Stasch
    Pharma Research Center, Bayer AG, Aprather Wey 18a, D 42096 Wuppertal, Germany
    Nature 410:212-5. 2001
    ..This results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and as such may offer an approach for treating cardiovascular diseases...
  63. ncbi p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription
    F Chiacchiera
    Laboratory of Signal dependent Transcription, Department of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro, CH 66030, Italy
    Cell Death Differ 16:1203-14. 2009
    ..Hence, inhibition of p38alpha affects the aerobic glycolytic metabolism specific of cancer cells and might be taken advantage of as a therapeutic strategy targeted against CRCs...
  64. ncbi ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells
    David A Claassen
    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198 6805, USA
    Mol Reprod Dev 76:722-32. 2009
    ..Together, these results argue that Y-27632 is a useful tool in overcoming obstacles to studies involving the cultivation of both hES cells and human iPS cells...
  65. ncbi In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)
    Jeffery J Anderson
    Department of Neuropharmacology, Merck Research Laboratories, MRLSDB1, 3535 General Atomics Court, San Diego, CA 92121, USA
    Eur J Pharmacol 473:35-40. 2003
    ..These findings demonstrate that [3H]methoxy-PEPy is useful for determining the occupancy of mGlu5 receptors in the brain...
  66. ncbi Management of advanced hepatocellular carcinoma in the era of targeted therapy
    Thomas Yau
    University Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong
    Liver Int 29:10-7. 2009
    ..Future progress seems likely to depend on using controlled clinical trials to optimize synergistic combination treatments...
  67. ncbi Activation of p38 MAPK in primary afferent neurons by noxious stimulation and its involvement in the development of thermal hyperalgesia
    Toshiyuki Mizushima
    Department of Anatomy and Neuroscience, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
    Pain 113:51-60. 2005
    ....
  68. ncbi A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    K N Chi
    Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
    Ann Oncol 19:746-51. 2008
    ..The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer...
  69. ncbi Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release
    Houman Homayoun
    Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Neuropsychopharmacology 29:1259-69. 2004
    ..By extension, these results suggest that pharmacological potentiation of mGlu5 receptors may ameliorate the cognitive and other behavioral abnormalities associated with NMDA receptor deficiency...
  70. ncbi A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
    S Steinbild
    Tumor Biology Center, Albert Ludwigs University Freiburg Freiburg, Germany
    Br J Cancer 97:1480-5. 2007
    ..Sorafenib has antitumour activity in HRPCP when evaluated for RECIST- and PSA-based response. Further investigation as a component of combination regimens is necessary to evaluate its definite or overall clinical benefit for HRPCP...
  71. ncbi Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
    Zheng Wang
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, PR China
    Clin Cancer Res 14:5124-30. 2008
    ..This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo...
  72. ncbi The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Stefan Blech
    Boehringer Ingelheim Pharma GmbH and Co KG, Department of Drug Metabolism and Pharmacokinetics, Biberach, Germany
    Drug Metab Dispos 36:386-99. 2008
    ..o. administration of dabigatran etexilate and that the potential for clinically relevant interactions between dabigatran and drugs metabolized by cytochrome P450 is low...
  73. ncbi Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 25:10414-9. 2005
    ..These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists...
  74. ncbi Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
    Bengt I Eriksson
    Department of Orthopaedic Surgery, Sahlgrenska University Hospital Ostra, Gothenburg, Sweden
    Lancet 370:949-56. 2007
    ..After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis...
  75. ncbi Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
    Lila Adnane
    Department of Cancer Research, Bayer Pharmaceutical Corp, West Haven, Connecticut, USA
    Methods Enzymol 407:597-612. 2006
    ..This agent is currently being evaluated in phase III clinical trials in renal cell and hepatocellular carcinomas...
  76. ncbi mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats
    Justin T Gass
    Department of Psychiatry and Behavioral Sciences, Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC 29425, USA
    Neuropsychopharmacology 34:820-33. 2009
    ....
  77. ncbi Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
    Christopher W Ryan
    Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 25:3296-301. 2007
    ..This phase II study evaluated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple receptor tyrosine kinase inhibitor, in patients with advanced renal carcinoma...
  78. ncbi Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
    Jared A Gollob
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:3288-95. 2007
    ..We undertook this study to determine the activity and tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-line therapy in metastatic renal cell cancer (RCC)...
  79. ncbi A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
    Keith T Flaherty
    The Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 14:4836-42. 2008
    ..Pharmacokinetic analyses were done for sorafenib on days 2 and 19 of cycle 1 and for paclitaxel on day 1 of cycles 1 and 2. Pretreatment tumor samples from 17 melanoma patients were analyzed for BRAF mutations...
  80. ncbi GABA transient sets the susceptibility of mIPSCs to modulation by benzodiazepine receptor agonists in rat hippocampal neurons
    Jerzy W Mozrzymas
    Laboratory of Neuroscience, Department of Biophysics, Wrocław Medical University, Chałubiñskiego 3, 50 368 Wroclaw, Poland
    J Physiol 585:29-46. 2007
    ..We conclude that an extremely brief agonist transient renders IPSCs particularly sensitive to the up-regulation of agonist binding by BDZs...
  81. ncbi Different transmitter transients underlie presynaptic cell type specificity of GABAA,slow and GABAA,fast
    Janos Szabadics
    Department of Anatomy and Neurobiology, University of California, 193 Irvine Hall, Irvine, CA 92697, USA
    Proc Natl Acad Sci U S A 104:14831-6. 2007
    ..These results reveal a form of GABA(A) receptor mediated communication by a dedicated cell type that produces slow ionotropic responses with properties intermediate between phasic and tonic inhibition...
  82. ncbi Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells
    Erika Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    Clin Cancer Res 16:4990-5001. 2010
    ..Cancer cell survival, invasion, and metastasis depend on cancer cell proliferation and on tumor-induced angiogenesis. We evaluated the efficacy of the combination of sorafenib and erlotinib or cetuximab...
  83. ncbi Validating γ oscillations and delayed auditory responses as translational biomarkers of autism
    Michael J Gandal
    Department of Psychiatry, University of Pennsylvania, Philadelphia, 19104, USA
    Biol Psychiatry 68:1100-6. 2010
    ..This study assessed the translational potential of auditory evoked-response endophenotypes of autism in parallel mouse and human studies of autism...
  84. ncbi A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
    Takaaki Sasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Res 71:6051-60. 2011
    ..These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients...
  85. ncbi Hedgehog signaling drives cellular survival in human colon carcinoma cells
    Tapati Mazumdar
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer Res 71:1092-102. 2011
    ..Collectively, these results highlight the importance of Gli activation downstream of Smo as a therapeutic target in models of human colon carcinoma...
  86. ncbi Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
    Hendrieke Hoftijzer
    Department of Endocrinology and Metabolism, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 161:923-31. 2009
    ..We studied the effects of the multitarget tyrosine kinase inhibitor sorafenib on the reinduction of RaI uptake and tumor progression...
  87. ncbi Formation and disassembly of adherens and tight junctions in the corneal endothelium: regulation by actomyosin contraction
    Charanya Ramachandran
    School of Optometry, Indiana University, Bloomington, Indiana, USA
    Invest Ophthalmol Vis Sci 51:2139-48. 2010
    ..However, these data on reassembly show that a contractile tone of the PAMR is essential for assembly of the apical junctional complex...
  88. ncbi BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache
    K A Maubach
    BTG International Ltd, 10 Fleet Place, Limeburner Lane, London, UK
    Br J Pharmacol 156:316-27. 2009
    ..This study reports the pharmacological characterization of BGC20-1531, a novel EP(4) receptor antagonist...
  89. ncbi Synthesis and biological evaluation of certain alpha,beta-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents
    H I El-Subbagh
    Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    J Med Chem 43:2915-21. 2000
    ..as chalcone analogues carrying variety of aryl and heteroaryl groups, pyrazolo[4,3-c]pyridines, pyridolo[4,3-c]pyrimidines, and pyrido[4,3-c]-pyridines, carrying an arylidene moiety, and a series of pyrano[3,..
  90. ncbi FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury
    Jerome Cau
    INSERM, U927, University Poitiers, Poitiers, France
    J Vasc Surg 49:728-40. 2009
    ....
  91. ncbi QSAR studies of bioactivities of 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 receptor ligands using physicochemical descriptors and MLR and ANN-modeling
    Mohammad Goodarzi
    Department of Chemistry, Faculty of Sciences, Islamic Azad University, Arak Branch, Arak, Markazi, Iran
    Eur J Med Chem 45:3911-5. 2010
    ..algorithm, and then used to built a QSAR model for a series of 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT(6) receptor agonists or antagonists, useful for the treatment of central nervous system disorders...
  92. ncbi A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy
    Federica Crostarosa
    Center for Biomedical Research, Population Council, New York, New York, United States of America
    PLoS ONE 4:e8060. 2009
    ..An animal model to investigate the underlying causes of the synergistic action of the two viruses and where preventative strategies can be tested under such complex physiological conditions is currently unavailable...
  93. ncbi Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers
    Qiaojie Xiong
    Departments of Neuroscience, Physiology and High Throughput Biology Center, School of Medicine, Johns Hopkins University, 733 North Broadway, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 105:3128-33. 2008
    ..The resultant combinatorial potentiation by multiple synthetic chemical openers indicates that KCNQ channels are accessible to various types and combinations of pharmacological regulation...
  94. ncbi Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions
    Masahide Nakajima
    Pharmaceuticals Research Unit, Mitsubishi Pharma Corporation, 1000, Kamoshida cho, Aoba ku, Kanagawa, 227 0033, Yokohama, Japan
    Eur J Pharmacol 459:113-20. 2003
    ..We conclude that Wf-536 has tumor anti-metastatic activity which may depend on inhibition of tumor motility and angiogenesis. The findings support its further clinical development as an anti-metastatic agent...
  95. ncbi In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
    Wolfgang Wienen
    Department of Pulmonary Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, 88397 Biberach, Germany
    Thromb Haemost 98:155-62. 2007
    ..These data suggest that dabigatran is a potent, selective thrombin inhibitor and an orally active anticoagulant as the prodrug, dabigatran etexilate...
  96. ncbi Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation
    Vahe Michael Zohrabian
    Department of Neurosurgery, New York Medical College, Valhalla, New York 10595, USA
    Anticancer Res 29:119-23. 2009
    ..Here, the involvement of the Rho and Rho-associated protein kinase (ROCK) pathway, along with MAPK, was investigated to determine their roles in GBM cell migration and proliferation...
  97. ncbi A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea
    K Iizuka
    First Department of Internal Medicine, Gunma University Faculty of Medicine, School of Medicine, 3 39 15 Showa Machi, Maebashi, Gunma, 371 8511, Japan
    Br J Pharmacol 128:925-33. 1999
    ....
  98. ncbi Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer
    George R Blumenschein
    The M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030 4009, USA
    J Clin Oncol 27:4274-80. 2009
    ..We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy...
  99. ncbi Changes in conformation and subcellular distribution of alpha4beta2 nicotinic acetylcholine receptors revealed by chronic nicotine treatment and expression of subunit chimeras
    Patricia C Harkness
    Department of Pharmacology, University College London, London, WC1E 6BT, United Kingdom
    J Neurosci 22:10172-81. 2002
    ..The finding that subunit conformation can be influenced by coassembled subunit partners is in agreement with models of receptor assembly which propose that subunit folding continues after initial subunit-subunit interactions...
  100. ncbi Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages
    Muthoni Junghae
    Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
    Infect Immun 70:5026-35. 2002
    ..Similar effects were observed in pretreated macrophages or in treatment of infected macrophages. These results suggests that p38 MAPK activation may have a potential therapeutic value in the treatment of visceral leishmaniasis...
  101. ncbi Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats
    Paul J Kenny
    Department of Neuropharmacology, CVN-7, The Scripps Research Institute, La Jolla, CA 92037, USA
    Psychopharmacology (Berl) 179:247-54. 2005
    ..Further, it is likely that blockade of mGlu5 receptors may attenuate cocaine consumption, at least in part, by decreasing the baseline activity of brain reward circuitries...

Research Grants71

  1. Pilot-Scale Heterocyclic and Carbocyclic Libraries for High Throughout Screening
    RICHARD LAROCK; Fiscal Year: 2007
    ..libraries of indoles, benzofurans, benzopyrans, coumarins, isocoumarins, phthalides, pyrones, 2-quinolones, pyridines, isoquinolin-1-ones, isoindolin-1-ones, isoquinolines, carbolines, isoindolo[2,1-a]indoles, carbazoles, ..
  2. Synthesis of Medicinally Important Heterocycles
    RICHARD LAROCK; Fiscal Year: 2007
    ..benzopyrans, chromones and heteroatom analogues, furans, thiophenes, pyrroles, oxazoles, isoxazoles, pyrazoles, pyridines, quinolines, coumarins, indenes, indenones, naphthols, and phenols...
  3. Au/Pt Catalysis in the Synthesis of Elaborate N-Heterocycles: Methodology Develop
    Liming Zhang; Fiscal Year: 2009
    ..g., pyridines, pyrroles, oxazoles, pyrroline and indoles)...
  4. Au/Pt Catalysis in the Synthesis of Elaborate N-Heterocycles: Methodology Develop
    Liming Zhang; Fiscal Year: 2010
    ..g., pyridines, pyrroles, oxazoles, pyrroline and indoles)...
  5. Carbon-Carbon Bond Forming Reactions Via C-H Activation
    Jonathan A Ellman; Fiscal Year: 2011
    ..will provide 1,2-dihydropyridines, which are extremely versatile intermediates in the synthesis of pyridines and piperidines...
  6. Carbon-Carbon Bond Forming Reactions Via C-H Activation
    Jonathan A Ellman; Fiscal Year: 2010
    ..will provide 1,2-dihydropyridines, which are extremely versatile intermediates in the synthesis of pyridines and piperidines...
  7. Carbon-Carbon Bond Forming Reactions Via C-H Activation
    JONATHAN ELLMAN; Fiscal Year: 2009
    ..will provide 1,2-dihydropyridines, which are extremely versatile intermediates in the synthesis of pyridines and piperidines...
  8. Approaches to Bioactive Aminoimidazole Natural Products
    CARL LOVELY; Fiscal Year: 2007
    ..Also, it is planned to establish the applicability of the rearrangement to imidazo[4,5-b]pyridines, if successful, the rearranged products might function as key intermediates in approaches to several monomeric ..
  9. DEVELOPING AN UNDERSTANDING OF ASYMMETRIC INDUCTION
    Patrick J Walsh; Fiscal Year: 2010
    ..to the synthesis of enantiomerically enriched heterocycles bearing important pharmacophores, such as furans and pyridines. We have also developed several new routes to pyranones, furanosidic aldehydes, furans, and pyrroles...
  10. DEVELOPING AN UNDERSTANDING OF ASYMMETRIC INDUCTION
    Patrick Walsh; Fiscal Year: 2007
    ..to the synthesis of enantiomerically enriched heterocycles bearing important pharmacophores, such as furans and pyridines. We have also developed several new routes to pyranones, furanosidic aldehydes, furans, and pyrroles...
  11. DEVELOPING AN UNDERSTANDING OF ASYMMETRIC INDUCTION
    Patrick J Walsh; Fiscal Year: 2010
    ..to the synthesis of enantiomerically enriched heterocycles bearing important pharmacophores, such as furans and pyridines. We have also developed several new routes to pyranones, furanosidic aldehydes, furans, and pyrroles...
  12. Synthetic Methods Involving Decarboxylative Coupling
    JON TUNGE; Fiscal Year: 2007
    ..amines, functionally differentiated hexadienes, and various biologically important heterocycles including pyridines, azetidines, and piperidines...
  13. Synthetic Methods Involving Decarboxylative Coupling
    Jon A Tunge; Fiscal Year: 2010
    ..amines, functionally differentiated hexadienes, and various biologically important heterocycles including pyridines, azetidines, and piperidines...
  14. Inhibitor of FtsZ Polymerization in M. tuberculosis
    Robert Reynolds; Fiscal Year: 2004
    ..The 2-alkoxy-carbonylamino-pyridines (2-ACPs) potently inhibit the growth of Mtb with an MIC99 (SRI-3072) as low as 0.15 microgram/ml (0...
  15. Design, Syntheses and Studies of Novel Antituberculosis Agents
    Marvin J Miller; Fiscal Year: 2010
    ..synthesized, potent, non-toxic, remarkably selective small molecule antiTB agents, including imidazo[1,2-a]pyridines, the development of which will be the second goal...
  16. ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
    Philip Fuchs; Fiscal Year: 2004
    ..the contribution of the central arene moiety to anticancer activity by testing pairs of unsymmetrical annulated pyridines derived from the best simplified hexacyclic steroidal subunits...
  17. Synthesis of (-)-cananodine, an alkaloid active against hepatocellular carcinoma
    JAMES VYVYAN; Fiscal Year: 2007
    ..cross-coupling of alkenyl triflates, alkenyl boronates, or alkylzinc reagents with highly substituted pyridines having complementary functionality; 2) preparation of tetrahydro-5H-cyclohepta[b]pyridine derivatives via an ..
  18. Pyridine Synthesis via an Olefin C-H Alkenylation/Azaelectrocyclization Strategy
    ASHLEY BERMAN; Fiscal Year: 2007
    ..This strategy allows for the concise stereoselective synthesis of pyridines, providing rapid access to this important class of compounds from readily available starting materials...
  19. SYNTHESIS & SYNTHETIC UTILITY OF 1-ACYLDIHYDROPYRIDINES
    DANIEL COMINS; Fiscal Year: 1990
    ..This will allow for development of novel syntheses of substituted pyridines through aromatization of the dihydropyridine intermediates...
  20. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2004
    ..The potential binding sites of SCH28080 and other imidazo-pyridines will be investigated by kinetic measurements in cells transfected with the H+,K+ ATPase and mutated enzyme...
  21. PERICYCLIC REACTIONS FOR ORGANIC SYNTHESIS
    RICK DANHEISER; Fiscal Year: 2001
    ..Heterocyclic variants of this process will be developed leading to substituted pyridines, dihydroisobenzofurans, and isoindoles...
  22. STUDIES IN ALKALOID TOTAL SYNTHESIS
    STEVEN WEINREB; Fiscal Year: 2003
    ..Finally, methodology for regioselective construction of highly substituted pyridines, which are components of the thiostreptone class of antibiotics, will be pursed via an intramolecular hetero ..